表 6. Global research hotspots on oncology: urinary system and reproductive system.
肿瘤领域全球研究热点——泌尿系统肿瘤与生殖系统肿瘤
| 研究主题 | 相关研究 | 被引次数
查询时间 2020.09.23 |
期刊来源 |
| 泌尿系统肿瘤 | |||
| 前列腺癌 | Randomized，double-blind，phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer[53] | 230 | J Clin Oncol |
| Apalutamide treatment and metastasis-free survival in prostate cancer[54] | 343 | N Engl J Med | |
| Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence：a prospective，randomized，multicenter phase II trial[55] | 298 | J Clin Oncol | |
| Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality：the CAP randomized clinical trial[56] | 118 | JAMA | |
| Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer[57] | 56 | J Clin Oncol | |
| Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe[58] | 36 | Eur Urol | |
| Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity，metastasis，and antiandrogen resistance[59] | 281 | Science | |
| 肾癌 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[60] | 247 | Science |
| Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma[61] | 233 | N Engl J Med | |
| 生殖系统肿瘤 | |||
| 奥拉帕利 | Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy：an updated analysis from a randomised，placebo-controlled，double-blind，phase 2 trial[62] | 204 | Lancet Oncol |
| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[63] | 391 | N Engl J Med | |
| Rucaparib | Rucaparib in relapsed，platinum-sensitive high-grade ovarian carcinoma（ARIEL2 Part 1）：an international，multicentre，open-label，phase 2 trial[64] | 439 | Lancet Oncol |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy（ARIEL3）：a randomised，double-blind，placebo-controlled，phase 3 trial[65] | 392 | Lancet | |